ArticleScientific reports2025
MCC950 targets the ROS-NEK7-NLRP3 axis to improve type 2 diabetic retinopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dysfunction of the Neurovascular Unit in Diabetic Retinopathy: Advances from Molecular Mechanisms to Targeted Interventions.Stem cell reviews and reports · 2026Review
- Article
- Vasant Kusumakar Rasa reduces neovascularisation, oxidative stress, inflammation and improves retinal function in diabetic rats.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
1 mM of MCC950 targets the ROS-NEK7-NLRP3 axis to ameliorate T2DM in rats and exhibits peak efficacy in improving retinopathy. It has been found that the specific inhibitor MCC950 can alleviate diabetic retinopathy by inhibiting NLRP3 inflammasome, but its concentration-dependent efficacy on retinal pathology needs to be explored. The aim of this study was to quantify the effects of intravitreal injection of graded concentrations of MCC950 (0.01, 0.1, 1,10 mM) on retinal structure and NLRP3 inflammasome signalling in type 2 diabetic male rats, and to reveal that 1 mM MCC950 may exert optimal retinoprotective effects by down-regulating the NEK7-NLRP3 pathway. Type 2 diabetic male rats induced by streptozotocin were administered intravitreal injections of MCC950 at varying concentrations (0.01, 0.1, 1, 10 mM). Quantitative assessments revealed that a concentration of 1 mM MCC950 markedly improved retinal histopathological alterations (p < 0.05) and modulated retinal apoptosis and oxidative stress to a considerable degree (p < 0.05). On a mechanistic level, MCC950 suppressed NLRP3 inflammasome activation by disrupting the interaction between NEK7 and NLRP3 (manifested by the down-regulation of pathway-associated protein expression, p<0.05) and a strong positive correlation between NEK7 and NLRP3 protein expression (r = 0.62, p = 0.19); inhibited the activation of the NLRP3 inflammasome (manifested by reduced levels of Cleaved Caspase-1, IL-1β, and IL-18, p < 0.001). There was a positive correlation between the intensity of ROS fluorescence and the fluorescence expression of NEK7 (r = 0.8857, p < 0.05), with MCC950 treatment significantly lowering retinal ROS levels at the 1 mM concentration. In conclusion, MCC950 inhibits ROS-mediated NEK7 upregulation, NLRP3 activation, and attenuates pathological damage, oxidative stress, retinal inflammation, and apoptosis in type 2 diabetic retina via ROS-NEK7-NLRP3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.